bioRxiv · 10.1101/2023.08.04.552064
Using human genetics to develop strategies to increase erythropoietic output from genome-edited hematopoietic stem and progenitor cells
Abstract
Human genetic polymorphisms result in a diversity of phenotypes. Some sequences are pathologic and lead to monogenic diseases, while others may confer beneficial traits. Genome editing is a powerful tool to recreate genotypes found in the population, including the ability to correct pathologic mutations. One of the best characterized naturally occurring mutations causing congenital erythrocytosis arises from a truncation in the erythropoietin receptor (tEPOR) which can result in non-pathogenic hyper-production of red blood cells (RBCs). Using the precision of CRISPR/Cas9 genome editing, we have recreated tEPOR and studied the effect of variations of the genotype on RBC development. We then combined tEPOR with a correction strategy developed for {beta}-thalassemia and demonstrated that coupling the two genome editing events gave RBCs a significant selective advantage. This demonstrates the potential of combining human genetics with the precision of genome editing to enable safer and more effective genome editing therapies for patients with serious genetic diseases.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Camarena, J., Luna, S. E., Hampton, J. P., Majeti, K. R., Charlesworth, C. T., Soupene, E., Sheehan, V. A., Cromer, M. K., Porteus, M. H.. 2023-08-04. Using human genetics to develop strategies to increase erythropoietic output from genome-edited hematopoietic stem and progenitor cells. https://doi.org/10.1101/2023.08.04.552064
Cite the original work for its findings. Save a collection to share your selection of sources.